Department of Dermatology and Allergy, University Hospital Würzburg, Würzburg, Germany.
Department of Dermatology and Allergy, University Hospital Würzburg, Würzburg, Germany.
J Allergy Clin Immunol Pract. 2016 Nov-Dec;4(6):1205-1212. doi: 10.1016/j.jaip.2016.05.018. Epub 2016 Jun 30.
Therapeutic options for pain management are restricted in patients with nonsteroidal anti-inflammatory drug (NSAID)-induced or NSAID-exacerbated urticaria because strong cyclooxygenase (COX)-I inhibiting NSAID cannot be used. Alternative NSAID such as weak COX-I inhibitors or selective COX-II inhibitors are sometimes not sufficiently effective or have potentially troublesome adverse effects.
To date, prophylactic premedication with H-antihistamines is rarely practiced in patients concurrently suffering from recurrent pain and NSAID-associated urticaria. Our data analysis aims to clarify whether prophylactic premedication before the intake of NSAID is effective, safe, and practicable.
Data of 21 patients with NSAID-induced or NSAID-exacerbated urticaria who underwent single dose NSAID provocation 30 minutes after premedication with 5 mg desloratadine were retrospectively evaluated.
After H-antihistamine premedication, 17 patients tolerated 16 single dose provocation tests with strong COX-I inhibitors and 2 tests with weak COX-I inhibitors. Despite H-antihistamine premedication, 2 patients developed acute urticaria after intake of 400 mg ibuprofen. Another 2 patients with acute urticaria after intake of 800 mg ibuprofen tolerated 400 mg ibuprofen and 1000 mg paracetamol, respectively.
In the majority of patients with NSAID-induced or NSAID-exacerbated urticaria concurrently suffering from intermittent pain, a premedication regimen with 5 mg desloratadine 30 minutes before intake of a strong COX-I inhibitor seems to be effective, safe, and practicable.
由于不能使用强环氧化酶 (COX)-I 抑制剂的非甾体抗炎药 (NSAID),因此,对于 NSAID 诱导或 NSAID 加重型荨麻疹患者,其疼痛管理治疗选择受到限制。替代 NSAID,如弱 COX-I 抑制剂或选择性 COX-II 抑制剂,有时效果不够理想或具有潜在的麻烦不良反应。
迄今为止,同时患有复发性疼痛和 NSAID 相关荨麻疹的患者很少预防性使用 H 抗组胺药。我们的数据分析旨在阐明 NSAID 摄入前预防性使用药物是否有效、安全和可行。
回顾性评估了 21 例 NSAID 诱导或 NSAID 加重型荨麻疹患者的数据,这些患者在 NSAID 单次剂量激发前 30 分钟接受了 5mg 地氯雷他定的预用药。
在 H 抗组胺药预用药后,17 例患者耐受了 16 次强 COX-I 抑制剂的单次剂量激发试验和 2 次弱 COX-I 抑制剂的激发试验。尽管进行了 H 抗组胺药预用药,但仍有 2 例患者在服用 400mg 布洛芬后出现急性荨麻疹,另有 2 例患者在服用 800mg 布洛芬后出现急性荨麻疹,分别耐受了 400mg 布洛芬和 1000mg 对乙酰氨基酚。
在大多数 NSAID 诱导或 NSAID 加重型荨麻疹同时伴有间歇性疼痛的患者中,在摄入强 COX-I 抑制剂前 30 分钟使用 5mg 地氯雷他定的预用药方案似乎是有效、安全且可行的。